Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Eye Diseases Clear all
Completed Phase 1Phase 2 Interventional Results available

Gene Therapy for Achromatopsia (CNGA3)

NCT03758404
View directory record Official record
Conditions
Achromatopsia
Interventions
adeno-associated virus vector AAV- CNGA3
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jul 22, 2026, 4:47 AM EDT
Recruiting No phase listed Observational

Pathogenesis and Genetics of Microphthalmia, Anophthalmia and Uveal Coloboma (MAC)

NCT01778543
View directory record Official record
Conditions
Coloboma, Anophthalmia, Microphthalmia
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Year to 100 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Rituximab for Graves' Ophthalmopathy

NCT00595335
View directory record Official record
Conditions
Thyroid-associated Ophthalmopathy
Interventions
Rituximab, Saline, Methylprednisolone
Drug
Lead sponsor
Rebecca Bahn
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Jul 22, 2026, 4:47 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

NCT01011374
View directory record Official record
Conditions
Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
Interventions
ranibizumab (Lucentis)
Drug
Lead sponsor
Retina Associates of Cleveland, Inc
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

NCT02028884
View directory record Official record
Conditions
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions
Satralizumab, Placebo, Baseline Treatment
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 74 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)

NCT03539549
View directory record Official record
Conditions
Macular Degeneration
Interventions
Abicipar pegol
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Not applicable Interventional

An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children

NCT00002015
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Roche Global Development
Other
Eligibility
3 Months to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Not applicable Interventional

iCare HOME2 Clinical Trial

NCT05162989
View directory record Official record
Conditions
Intraocular Pressure, Glaucoma
Interventions
iCare HOME2 vs iCare IC200
Device
Lead sponsor
Icare Finland Oy
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

NCT00085189
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Mucosal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIC Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma
Interventions
gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen, multi-epitope melanoma peptide vaccine, incomplete Freund's adjuvant, Montanide ISA 51 VG, agatolimod sodium, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jul 22, 2026, 4:47 AM EDT
Recruiting Not applicable Interventional

Wearable Technology to Characterize and Treat mTBI Subtypes: Biofeedback-Based Precision Rehabilitation

NCT06381674
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Concussion, Rehabilitation, Balance Impairment
Interventions
Vestibular therapy for mTBI augmented with audio and visual real-time biofeedback, Vestibular therapy for mTBI
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Portland, Oregon • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Active, not recruiting No phase listed Observational

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT06161584
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
34
States / cities
Bakersfield, California • Beverly Hills, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears

NCT01614847
View directory record Official record
Conditions
Dry Eye
Interventions
Artificial tears
Drug
Lead sponsor
Thomas O Salmon, OD, PhD
Other
Eligibility
18 Years to 35 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tahlequah, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)

NCT01301443
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Subretinally injected RetinoStat
Drug
Lead sponsor
Oxford BioMedica
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Not applicable Interventional Results available

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

NCT02798289
View directory record Official record
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
Oculeve Intranasal Neurostimulator
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Artesia, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Jul 22, 2026, 4:47 AM EDT
Completed No phase listed Observational

Phacoemulsification Sleeves

NCT00289068
View directory record Official record
Conditions
Cataract
Interventions
Phacoemulsification Sleeve surgery, Phacoemulsification Sleeves surgery, Phacoemulsification Sleeves
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

NCT01002950
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy
Interventions
ACU-4429, Matching placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Phoenix, Arizona • Beverly Hills, California • Daytona Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Jul 22, 2026, 4:47 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Wearable Echolocation Aids Using Parametric Sound

NCT07218991
View directory record Official record
Conditions
Low Vision
Interventions
Wearable Echolocation Device
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Recruiting Not applicable Interventional

Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers

NCT06629649
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment.
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Terminated Early Phase 1 Interventional

COVID-19 Vaccination in Rheumatic Disease Patients

NCT04839315
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis
Interventions
mRNA COVD19 vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05376176
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
STN1010904 ophthalmic suspension 0.03% BID, STN1010904 ophthalmic suspension 0.1% BID, Placebo (Vehicle) BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer

NCT00004189
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, becatecarin, cisplatin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration

NCT00001615
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Corticosteroid
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 4:47 AM EDT
Completed No phase listed Observational

A Real-World Evidence (RWE) Long-Term Follow-Up Study to Assess Outcomes of Alcon Monofocal Intraocular Lenses

NCT05799950
View directory record Official record
Conditions
Aphakia
Interventions
AcrySof single-piece IOL, AcrySof multi-piece IOL
Device
Lead sponsor
Alcon Research
Industry
Eligibility
Not listed
Enrollment
138 participants
Timeline
2023 – 2025
U.S. locations
6
States / cities
Burbank, California • Jacksonville, Florida • Rock Island, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

DOMPE -MT Neurotrophic Keratitis

NCT06947850
View directory record Official record
Conditions
Dry Eye, Neurotrophic Keratitis
Interventions
Cenegermin Ophthalmic Solution [Oxervate]
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jul 22, 2026, 4:47 AM EDT